M-145

Milnacipran hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant^®

• 実験式（ヒル表記法）: C₁₅H₂₃ClN₂O
• CAS番号: 101152-94-7
• 分子量: 282.81
• EC Number: 200-659-6
• MDL番号: MFCD27978092
• UNSPSCコード: 41116107
• PubChem Substance ID: 329817879
• NACRES: NA.24

特性

• グレード: certified reference material
• 形状: liquid
• 特徴: Snap-N-Spike^®/Snap-N-Shoot^®
• 包装: ampule of 1 mL
• メーカー／製品名: Cerilliant^®
• 濃度: 1.0 mg/mL in methanol (as free base)
• テクニック: gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• アプリケーション: clinical testing
• フォーマット: single component solution
• 保管温度: −20°C
• SMILES記法: CCN(CC)C([C@]1(C2=CC=CC=C2)C[C@@H]1CN)=O.Cl
• InChI: 1S/C15H22N2O.ClH/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12;/h5-9,13H,3-4,10-11,16H2,1-2H3;1H/t13-,15+;/m1./s1
• InChI Key: XNCDYJFPRPDERF-PBCQUBLHSA-N

詳細

詳細

Milnacipran, sold under the brand names Savella^®, Ixel^®, Dalcipran^®, or Toledomin, is a serotonin-norepinephrine reuptake inhibitor (SNRI) used in the treatment of depression. In 2009, the US Food and Drug Administration (FDA) approved milnacipran for management of the chronic pain disorder fibromyalgia, making it only the third drug approved in the US for this indication besides duloxetine and pregabalin.

アプリケーション

• Anesthetic and Analgesic Applications of Milnacipran: Review on new serotonin-norepinephrine reuptake inhibitors, highlighting Milnacipran hydrochloride′s role in anesthetic and analgesic applications, discussing its impact on pain management strategies (Fanelli et al., 2021).


• Sustained Release Delivery System for Milnacipran: Development of a novel chitosan-polycaprolactone based mucoadhesive gastro-retentive drug delivery system for Milnacipran HCl, aimed at improving bioavailability and enhancing patient compliance (Hussain et al., 2020).


• Comparative Review of Levomilnacipran and Milnacipran: Analysis of Levomilnacipran′s effectiveness compared to Milnacipran in treating major depressive disorder, focusing on efficacy, tolerability, and patient outcomes (Gautam et al., 2019).


• Antidepressant Efficacy and Side Effects: Network meta-analysis of 21 antidepressants, including Milnacipran, assessing their side effect profiles and comparative tolerability in the acute treatment of major depression (Tomlinson et al., 2019).

法的情報

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Dalcipran is a registered trademark of Pierre Fabre Medicament

Ixel is a registered trademark of Pierre Fabre Medicament

Savella is a registered trademark of Forest Laboratories, Inc.

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

安全性情報

• ピクトグラム: GHS02,GHS06,GHS08
• シグナルワード: Danger
• 危険有害性情報: H225,H301 + H311 + H331,H370
• 注意書き: P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311
• 危険有害性の分類: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• ターゲットの組織: Eyes
• 保管分類コード: 3 - Flammable liquids
• WGK: WGK 1
• 引火点(°F): 49.5 °F - closed cup
• 引火点(℃): 9.7 °C - closed cup